Abstract
Metal ions play important roles in Aβ aggregate deposition and neurotoxicity which involves the formation of reactive oxygen species (ROS). Oxidative stress and metal dysregulation have been considered as therapeutic targets for AD. Herein, a novel double delivery platform has been presented by integrated anti-aggregation property of metal chelators and anti-oxidation property of CeO2NPs in one system for Alzheimer's disease treatment. Compared with metal chelators or CeO2NPs alone, a synergistic effect is observed in our H2O2-responsive controlled release system. So far, there is no report to use CeO2NP as both capping and antioxidant agent for AD therapy. By taking advantage of good biocompatibility, high selectivity toward toxic metal ions, and their ability to cross the blood–brain barrier (BBB), the two-in-one bifunctional nanoparticles can effectively inhibit Aβ aggregate formation, decrease cellular ROS and protect cells from Aβ-related toxicity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
